219 related articles for article (PubMed ID: 33256275)
1. [Introduction to the APASL clinical guidelines on the management of metabolic-associated fatty liver disease].
Shi YW; Xiao QQ; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2020 Nov; 28(11):915-917. PubMed ID: 33256275
[TBL] [Abstract][Full Text] [Related]
2. NONALCOHOLIC FATTY LIVER DISEASE BRAZILIAN SOCIETY OF HEPATOLOGY CONSENSUS.
Cotrim HP; Parise ER; Figueiredo-Mendes C; Galizzi-Filho J; Porta G; Oliveira CP
Arq Gastroenterol; 2016; 53(2):118-22. PubMed ID: 27305420
[TBL] [Abstract][Full Text] [Related]
3. MAFLD, patient-centred care, and APASL.
Sarin SK; Eslam M; Fan JG; Lin HC; George J; Omata M
Hepatol Int; 2022 Oct; 16(5):1032-1034. PubMed ID: 36070122
[TBL] [Abstract][Full Text] [Related]
4. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.
Chan WK; Tan SS; Chan SP; Lee YY; Tee HP; Mahadeva S; Goh KL; Ramli AS; Mustapha F; Kosai NR; Raja Ali RA
J Gastroenterol Hepatol; 2022 May; 37(5):795-811. PubMed ID: 35080048
[TBL] [Abstract][Full Text] [Related]
5. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso).
Moreira RO; Valerio CM; Villela-Nogueira CA; Cercato C; Gerchman F; Lottenberg AMP; Godoy-Matos AF; Oliveira RA; Brandão Mello CE; Álvares-da-Silva MR; Leite NC; Cotrim HP; Parisi ER; Silva GF; Miranda PAC; Halpern B; Pinto Oliveira C
Arch Endocrinol Metab; 2023 Nov; 67(6):e230123. PubMed ID: 38048417
[TBL] [Abstract][Full Text] [Related]
6. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment.
Wong VW; Chan WK; Chitturi S; Chawla Y; Dan YY; Duseja A; Fan J; Goh KL; Hamaguchi M; Hashimoto E; Kim SU; Lesmana LA; Lin YC; Liu CJ; Ni YH; Sollano J; Wong SK; Wong GL; Chan HL; Farrell G
J Gastroenterol Hepatol; 2018 Jan; 33(1):70-85. PubMed ID: 28670712
[No Abstract] [Full Text] [Related]
7. Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease".
Xu X; Nan Y
J Hepatol; 2022 Feb; 76(2):484-485. PubMed ID: 34774637
[No Abstract] [Full Text] [Related]
8. [Advances in diagnosis and treatment of nonalcoholic fatty liver disease].
Zhu C; Zhou D; Fan J
Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):81-4. PubMed ID: 26983471
[TBL] [Abstract][Full Text] [Related]
9. [An interpretation of European guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease].
Xin FZ; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):403-5. PubMed ID: 27465941
[TBL] [Abstract][Full Text] [Related]
10. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China).
Fan JG; Wei L; Zhuang H;
J Dig Dis; 2019 Apr; 20(4):163-173. PubMed ID: 30444584
[No Abstract] [Full Text] [Related]
11. Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) - April 2022 - AWMF Registration No.: 021-025.
;
Z Gastroenterol; 2022 Sep; 60(9):e733-e801. PubMed ID: 36100201
[No Abstract] [Full Text] [Related]
12. [Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)].
Chinese Society of Hepatology, Chinese Medical Association
Zhonghua Gan Zang Bing Za Zhi; 2024 May; 32(5):418-434. PubMed ID: 38858192
[TBL] [Abstract][Full Text] [Related]
13. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Watanabe S; Hashimoto E; Ikejima K; Uto H; Ono M; Sumida Y; Seike M; Takei Y; Takehara T; Tokushige K; Nakajima A; Yoneda M; Saibara T; Shiota G; Sakaida I; Nakamuta M; Mizuta T; Tsubouchi H; Sugano K; Shimosegawa T; ;
J Gastroenterol; 2015 Apr; 50(4):364-77. PubMed ID: 25708290
[TBL] [Abstract][Full Text] [Related]
14. [Non-alcoholic fatty liver disease, as a component of the metabolic syndrome, and its causal correlations with other extrahepatic diseases].
Halmos T; Suba I
Orv Hetil; 2017 Dec; 158(52):2051-2061. PubMed ID: 29285942
[TBL] [Abstract][Full Text] [Related]
15. Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis: Consensus-Based Recommendations From a Multidisciplinary Group of Experts.
Carrascosa JM; Vilarrasa E; Belinchón I; Herranz P; Crespo J; Guimerá F; Olveira A;
Actas Dermosifiliogr; 2023 May; 114(5):392-401. PubMed ID: 36720362
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the burden and variability in the management of NAFLD patients in the clinical practice: unifying the required criteria.
Sánchez-Torrijos Y; Ampuero J; Pérez Palacios D; Gallego-Durán R; Romero-Gómez M
Rev Esp Enferm Dig; 2019 Apr; 111(4):270-274. PubMed ID: 30810332
[TBL] [Abstract][Full Text] [Related]
17. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa.
Shiha G; Alswat K; Al Khatry M; Sharara AI; Örmeci N; Waked I; Benazzouz M; Al-Ali F; Hamed AE; Hamoudi W; Attia D; Derbala M; Sharaf-Eldin M; Al-Busafi SA; Zaky S; Bamakhrama K; Ibrahim N; Ajlouni Y; Sabbah M; Salama M; Anushiravani A; Afredj N; Barakat S; Hashim A; Fouad Y; Soliman R
Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):57-64. PubMed ID: 33181119
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
[TBL] [Abstract][Full Text] [Related]
19. The association of non-alcoholic fatty liver disease and metabolic syndrome in a Chinese population.
Lee SW; Lee TY; Yang SS; Peng YC; Yeh HZ; Chang CS
Hepatobiliary Pancreat Dis Int; 2017 Apr; 16(2):176-180. PubMed ID: 28381382
[TBL] [Abstract][Full Text] [Related]
20. Advancing the global public health agenda for NAFLD: a consensus statement.
Lazarus JV; Mark HE; Anstee QM; Arab JP; Batterham RL; Castera L; Cortez-Pinto H; Crespo J; Cusi K; Dirac MA; Francque S; George J; Hagström H; Huang TT; Ismail MH; Kautz A; Sarin SK; Loomba R; Miller V; Newsome PN; Ninburg M; Ocama P; Ratziu V; Rinella M; Romero D; Romero-Gómez M; Schattenberg JM; Tsochatzis EA; Valenti L; Wong VW; Yilmaz Y; Younossi ZM; Zelber-Sagi S;
Nat Rev Gastroenterol Hepatol; 2022 Jan; 19(1):60-78. PubMed ID: 34707258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
